<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aethlon Medical Inc — News on 6ix</title>
<link>https://6ix.com/company/aethlon-medical-inc</link>
<description>Latest news and press releases for Aethlon Medical Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aethlon-medical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683542fc78dffbe2df0e187c.webp</url>
<title>Aethlon Medical Inc</title>
<link>https://6ix.com/company/aethlon-medical-inc</link>
</image>
<item>
<title>Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-inc-advances-to-final-cohort-in-oncology-clinical-trial-following-positive-dsmb-review</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-inc-advances-to-final-cohort-in-oncology-clinical-trial-following-positive-dsmb-review</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon</description>
</item>
<item>
<title>OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCR</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/otc-markets-hosts-virtual-investor-presentation-with-jim-frakes-ceo-and-cfo-of-aethlon-medical-and-m-marin-senior-analyst-at-zacks-scr</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/otc-markets-hosts-virtual-investor-presentation-with-jim-frakes-ceo-and-cfo-of-aethlon-medical-and-m-marin-senior-analyst-at-zacks-scr</guid>
<pubDate>Wed, 18 Mar 2026 15:46:00 GMT</pubDate>
<description>NASDAQ: AEMD Lili Elston: Hello, and welcome to the Life Sciences Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we are very pleased you've joined us. The next presentation of the day is from Aethlon Medical . Their session will be moderated by M. Marin, Senior Analyst with Zacks Small Cap Research . Please note, you may submit questions for the presenter.</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-8</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-8</guid>
<pubDate>Fri, 13 Mar 2026 12:35:00 GMT</pubDate>
<description>NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging tec</description>
</item>
<item>
<title>Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-engages-maxim-group-llc-to-evaluate-strategic-opportunities-5</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-engages-maxim-group-llc-to-evaluate-strategic-opportunities-5</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th-3</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th-3</guid>
<pubDate>Tue, 10 Mar 2026 14:21:00 GMT</pubDate>
<description>Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the on</description>
</item>
<item>
<title>Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-to-present-at-the-life-sciences-investor-forum-on-march-12th-32</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-to-present-at-the-life-sciences-investor-forum-on-march-12th-32</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live,</description>
</item>
<item>
<title>Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/presenting-on-emerging-growth-conference-90-day-1-on-february-25-register-to-live-stream-4</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/presenting-on-emerging-growth-conference-90-day-1-on-february-25-register-to-live-stream-4</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>MIAMI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com</description>
</item>
<item>
<title>Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-to-present-on-the-emerging-growth-conference-on-february-25th-2026</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-to-present-on-the-emerging-growth-conference-on-february-25th-2026</guid>
<pubDate>Mon, 23 Feb 2026 13:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.</description>
</item>
<item>
<title>Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-fiscal-q3-211500859</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-fiscal-q3-211500859</guid>
<pubDate>Thu, 12 Feb 2026 21:15:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.</description>
</item>
<item>
<title>Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-release-fiscal-third-130100280</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-release-fiscal-third-130100280</guid>
<pubDate>Wed, 04 Feb 2026 13:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026.</description>
</item>
<item>
<title>Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-pricing-private-141500426</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-pricing-private-141500426</guid>
<pubDate>Fri, 05 Dec 2025 14:15:00 GMT</pubDate>
<description>Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced a</description>
</item>
<item>
<title>Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-publication-preclinical-130100619</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-publication-preclinical-130100619</guid>
<pubDate>Tue, 02 Dec 2025 13:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publication of a pre-clinical study entitled "Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin" in the pre-print online archive bioRxiv: https://www.biorxiv.org/cgi/content/short/2025.11.21.</description>
</item>
<item>
<title>Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-fiscal-q2-211500075</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-fiscal-q2-211500075</guid>
<pubDate>Wed, 12 Nov 2025 21:15:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.</description>
</item>
<item>
<title>Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-release-fiscal-second-130100921</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-release-fiscal-second-130100921</guid>
<pubDate>Fri, 07 Nov 2025 13:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025.</description>
</item>
<item>
<title>Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medicals-hemopurifier-shows-changes-120100490</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medicals-hemopurifier-shows-changes-120100490</guid>
<pubDate>Tue, 07 Oct 2025 12:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia. The study is a safety, feasibility, and dose-finding trial evaluating the company's Hemopurifier (HP) in patients with cancer not responding to anti-PD-1 therapy.</description>
</item>
<item>
<title>Aethlon Medical Announces Pricing of $4.5 Million Public Offering</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-pricing-4-131500631</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-pricing-4-131500631</guid>
<pubDate>Thu, 04 Sep 2025 13:15:00 GMT</pubDate>
<description>Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 5,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrant.</description>
</item>
<item>
<title>Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-issuance-hemopurifier-120100349</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-issuance-hemopurifier-120100349</guid>
<pubDate>Wed, 03 Sep 2025 12:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) announced that U.S. Patent No. 12,409,260 (the "260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the "453 Patent") directed to the treatment of COVID-19-associated coagulopathy ("CAC") issued July 9, 2025.</description>
</item>
<item>
<title>Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-financial-results-201500334</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-announces-financial-results-201500334</guid>
<pubDate>Wed, 13 Aug 2025 20:15:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments.</description>
</item>
<item>
<title>Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-release-fiscal-first-120100286</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-release-fiscal-first-120100286</guid>
<pubDate>Tue, 05 Aug 2025 12:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2025, at 4:15 p.m. ET on Wednesday, August 13, 2025.</description>
</item>
<item>
<title>Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort</title>
<link>https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-inc-announces-positive-120100822</link>
<guid isPermaLink="true">https://6ix.com/company/aethlon-medical-inc/news/aethlon-medical-inc-announces-positive-120100822</guid>
<pubDate>Tue, 15 Jul 2025 12:01:00 GMT</pubDate>
<description>Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification.</description>
</item>
</channel>
</rss>